Literature DB >> 2766240

Clinical-cytogenetic correlations in myelodysplasia (preleukemia).

R V Pierre1, D Catovsky, G J Mufti, G J Swansbury, C Mecucci, G W Dewald, T Ruutu, H Van Den Berghe, J D Rowley, F Mitelman.   

Abstract

Cytogenetic studies detected abnormalities in 107 (43%) of the 247 patients in this series. Some degree of overt clinical progression occurred in 55 patients (22%), this being 29% of those patients with cytogenetic abnormalities and 17% of those with normal chromosomes. The presence and complexity of a clonal cytogenetic abnormality correlated with shorter survival. In each clone category of a complexity classification (simple, complex, very complex), patients with some normal cells appeared to have better survival than those with none. In multiple regression analyses, the prognostic value of chromosomes was independent of (and second in importance to) the FAB type of myelodysplastic syndrome (MDS) whichever chromosome classification was used. Patients with refractory anemia (RA) had the lowest incidence of chromosome abnormalities and no cases were found to have only abnormal cells (AA). A greater proportion of patients with refractory anemia with an excess of blasts (RAEB) and RAEB in transformation (RAEB-t) had clonal abnormalities. Morphology alone is not at present able to distinguish between RA or refractory anemia with ringed sideroblasts and similar disorders that may not be MDS in the strict sense. Demonstration of a clonal cytogenetic abnormality remains a positive indication of the presence of the neoplastic nature of the disease.

Entities:  

Mesh:

Year:  1989        PMID: 2766240     DOI: 10.1016/0165-4608(89)90021-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.

Authors:  D Marisavljević; Z Rolović; D Sefer; N Basara; D Ilić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma.

Authors:  Gordon W Dewald
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

4.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

Review 5.  The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores.

Authors:  O Căzăceanu; Am Vlădăreanu; H Bumbea; M Begu; M Onisai; C Enache
Journal:  J Med Life       Date:  2014-09-25

6.  Prognostic impact of chromosome aberrations in ovarian cancer.

Authors:  T Pejovic; A Himmelmann; S Heim; N Mandahl; U M Flodérus; S Furgyik; B Elmfors; G Helm; H Willén; F Mitelman
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

Review 7.  Cytogenetic features in myelodysplastic syndromes.

Authors:  Detlef Haase
Journal:  Ann Hematol       Date:  2008-04-15       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.